Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: A prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients

✍ Scribed by Guillevin, Loïc ;Cohen, Pascal ;Mahr, Alfred ;Arène, Jean-Pierre ;Mouthon, Luc ;Puéchal, Xavier ;Pertuiset, Edouard ;Gilson, Brigitte ;Hamidou, Mohamed ;Lanoux, Patricia ;Bruet, Alain ;Ruivard, Marc ;Vanhille, Philippe ;Cordier, Jean-François

• Publisher: John Wiley and Sons
• Year: 2003
• Tongue: English
• Weight: 135 KB
• Volume: 49
• Category: Article
• ISSN: 0004-3591
• DOI: 10.1002/art.10922

✦ Synopsis

Abstract

Objective

Because the optimal cyclophosphamide (CY) treatment duration for severe polyarteritis nodosa (PAN) without virus infection and microscopic polyangiitis (MPA) has not been established, we conducted a trial to compare the effectiveness of 6 versus 12 CY pulses given in combination with corticosteroids (CS).

Methods

Sixty‐five (18 PAN, 47 MPA) previously untreated patients were randomized to receive 12 (n = 34) or 6 (n = 31) CY pulses combined with CS. PAN and MPA were histologically proven or met ACR criteria. All patients presented ≥1 factor of severity according to the five factor score (FFS). CY pulses were administered every 2 weeks for 1 month, then every 4 weeks. The end point of the study was the number of events (relapses and/or deaths) occurring in each group, analyzed according to an intention‐to‐treat strategy. The outcome was evaluated by Cox proportional hazards analysis.

Results

The baseline characteristics were similar for both groups. The mean (± SD) followup was 32 ± 21 months. Survival analysis showed a significantly lower relapse probability (P = 0.02; hazards ratio [HR] = 0.34) and higher event‐free survival (P = 0.02, HR = 0.44) for the 12 CY‐pulse group while the mortality rates were not significantly different (P = 0.47).

Conclusion

These results suggest that 6 CY pulses are less effective than 12 CY pulses to treat severe PAN and MPA, particularly with respect to the risk of relapses.